Table 1.

Epidemiologic studies of statins and breast cancer incidence

Study	Design	Patients, n	Breast cancer odds or hazard ratio (95% CI)	Hormone receptor subset analysis odds or hazard ratio (95% CI)	Statin subset analysis odds or hazard ratio (95% CI)
Beck et al. [39]	Case control	67,472	1.09 (0.93–1.28)	None	None
Blais et al. [55]	Case control	6721	0.67 (0.33–1.38)	None	None
Graaf et al. [37]	Case control	20,105	1.07 (0.65–1.74)	None	None
Kaye and Jick [40]	Case control	18,088	0.9 (0.6–1.3)	None	None
Kochhar et al. [41]	Case control	40,421	0.49 (0.38–0.62)	None	None
Boudreau et al. [9]	Case control	1982	0.9 (0.7–1.2)	None	Lipophilic 0.8–1.2; hydrophilic 1.0 (0.5–1.7)
Pocobelli et al. [38]	Case control	8620	1.0 (0.8–1.2)	None	Lipophilic 1.0 (0.8–1.2); (fl uvastatin 0.5 [0.3–0.8]); hydrophilic 1.2 (0.9–1.8)
Kumar et al. [50••]	Case only	2141	None	Negative 0.63 (0.43–0.92)	None
Cauley et al. [45]	Cohort	7528	0.30 (0.10–0.94)	None	None
Eliassen et al. [43]	Cohort	75,828	0.91 (0.76–1.08)	Positive 0.98 (0.79–1.22); negative 0.96  (0.60–1.51)	None
Boudreau et al. [44]	Cohort	92,788	1.07 (0.88–1.29)	Positive 1.06 (0.85–1.32); negative 1.28  (0.78–2.08)	Lipophilic 1.0 (0.8–1.26); hydrophilic 1.01  (0.48–2.13)
Cauley et al. [42••]	Cohort	156,351	0.91 (0.80–1.05)	Positive 0.97 (0.83–1.13); negative 0.83  (0.55–1.25)	Lipophilic 0.82 (0.70–0.97)

Meta-analyses of statins and breast cancer incidence
Study	Studies included	Breast cancer odds or risk ratio (95% CI)	Statin subset analysis odds or hazard ratio (95% CI)
Bonovas et al. [46]	7 randomized trials;  9 observational studies	1.03 (0.93–1.14)	None
Dale et al. [49]	5 randomized trials	1.33 (0.79–2.26)	Lipophilic 1.01 (0.82–1.25); hydrophilic 1.00 (0.90–1.11)
Browning and Martin [48]	7 randomized trials;  9 observational studies	Randomized trials: 1.01 (0.79–1.30); observational studies: 0.96 (0.90–1.04)	Lipophilic 0.89 (0.62–1.27); hydrophilic 1.15  (0.81–1.64)
Kuoppala et al. [47•]	17 total studies	1.04 (0.74–19)	Lipophilic 0.74–1.4; hydrophilic 3.3 (1.7–6.3)